Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(21 sites)
United States
HonorHealth Research Institute, Scottsdale, Arizona The University of Arizona Cancer Center, Tucson, Arizona USC - Norris Comprehensive Cancer Center, Los Angeles, California University of California Davis Comprehensive Cancer Center, Sacramento, California University of California San Francisco, San Francisco, California University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida The University of Chicago Comprehensive Cancer Center, Chicago, Illinois University of Kentucky Markey Cancer Center, Lexington, Kentucky Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland Hackensack University Medical Center, Hackensack, New Jersey NYU Langone Health, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York Duke Cancer Institute, Durham, North Carolina Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania Fox Chase Cancer Center, Philadelphia, Pennsylvania Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee Vanderbilt University Medical Center, Nashville, Tennessee Mary Crowley Cancer Research, Dallas, Texas Baylor University Medical Center, Dallas, Texas MD Anderson Cancer Center, Houston, Texas Fred Hutchinson Cancer Center, Seattle, Washington